SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE:A) today announced that Erasmus Medical Center, Rotterdam, Netherlands, has selected the Agilent SureSelect XT Human All Exon target enrichment system along with the Agilent Bravo automated liquid-handling platform as part of the Erasmus Rucphen Family study to identify genetic risk factors for some complex genetic disorders.
